Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Reich

Showing results (141-150 of 265) with videos related to

Pageof 27
Sort By:
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
European Journal of Dermatology : EJD|August 4, 2007
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasisKristian Reich, Frank O Nestle, Ying Wu, et al.
Journal of the American Academy of Dermatology|June 21, 2015
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialDiamant Thaçi, Andrew Blauvelt, Kristian Reich, et al.
The Journal of Allergy and Clinical Immunology|March 20, 2016
Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitisKristian Reich, Julia Deinzer, Anne-Kathrin Fiege, et al.
Dermatology Practical & Conceptual|June 1, 2022
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H TrialKristian Reich, Lars Erik Kristensen, Saxon D Smith, et al.
Journal of the American Academy of Dermatology|December 18, 2007
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 yearPhoebe Rich, Christopher E M Griffiths, Kristian Reich, et al.
Dermatology and Therapy|June 27, 2026
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc AnalysisStephen Weidinger, Kristian Reich, Naiem Issa, et al.
Lancet (London, England)|October 18, 2005
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialKristian Reich, Frank O Nestle, Kim Papp, et al.
The Journal of Dermatology|October 22, 2019
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2Kristian Reich, Michael Song, Shu Li, et al.
Dermatology and Therapy|December 16, 2021
Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSOKristian Reich, Bernhard Korge, Nina Magnolo, et al.
Pageof 27

Showing results (141-150 of 265) with videos related to

Sort By:
Pageof 27
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
European Journal of Dermatology : EJD|August 4, 2007
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasisKristian Reich, Frank O Nestle, Ying Wu, et al.
Journal of the American Academy of Dermatology|June 21, 2015
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialDiamant Thaçi, Andrew Blauvelt, Kristian Reich, et al.
The Journal of Allergy and Clinical Immunology|March 20, 2016
Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitisKristian Reich, Julia Deinzer, Anne-Kathrin Fiege, et al.
Dermatology Practical & Conceptual|June 1, 2022
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H TrialKristian Reich, Lars Erik Kristensen, Saxon D Smith, et al.
Journal of the American Academy of Dermatology|December 18, 2007
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 yearPhoebe Rich, Christopher E M Griffiths, Kristian Reich, et al.
Dermatology and Therapy|June 27, 2026
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc AnalysisStephen Weidinger, Kristian Reich, Naiem Issa, et al.
Lancet (London, England)|October 18, 2005
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialKristian Reich, Frank O Nestle, Kim Papp, et al.
The Journal of Dermatology|October 22, 2019
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2Kristian Reich, Michael Song, Shu Li, et al.
Dermatology and Therapy|December 16, 2021
Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSOKristian Reich, Bernhard Korge, Nina Magnolo, et al.
Pageof 27